290 related articles for article (PubMed ID: 19729836)
1. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.
Li JH; Chou CL; Li B; Gavrilova O; Eisner C; Schnermann J; Anderson SA; Deng CX; Knepper MA; Wess J
J Clin Invest; 2009 Oct; 119(10):3115-26. PubMed ID: 19729836
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
Olesen ET; Rützler MR; Moeller HB; Praetorius HA; Fenton RA
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12949-54. PubMed ID: 21768374
[TBL] [Abstract][Full Text] [Related]
3. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
[TBL] [Abstract][Full Text] [Related]
4. Combination of secretin and fluvastatin ameliorates the polyuria associated with X-linked nephrogenic diabetes insipidus in mice.
Procino G; Milano S; Carmosino M; Barbieri C; Nicoletti MC; Li JH; Wess J; Svelto M
Kidney Int; 2014 Jul; 86(1):127-38. PubMed ID: 24522493
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin modulates renal water reabsorption in vivo through increased AQP2 availability at the apical plasma membrane of collecting duct cells.
Procino G; Barbieri C; Carmosino M; Tamma G; Milano S; De Benedictis L; Mola MG; Lazo-Fernandez Y; Valenti G; Svelto M
Pflugers Arch; 2011 Nov; 462(5):753-66. PubMed ID: 21858457
[TBL] [Abstract][Full Text] [Related]
6. Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts.
Gao M; Cao R; Du S; Jia X; Zheng S; Huang S; Han Q; Liu J; Zhang X; Miao Y; Kang J; Gustafsson JÅ; Guan Y
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8397-402. PubMed ID: 26100911
[TBL] [Abstract][Full Text] [Related]
7. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
Ando F; Mori S; Yui N; Morimoto T; Nomura N; Sohara E; Rai T; Sasaki S; Kondo Y; Kagechika H; Uchida S
Nat Commun; 2018 Apr; 9(1):1411. PubMed ID: 29650969
[TBL] [Abstract][Full Text] [Related]
8. Integrin-linked kinase regulates tubular aquaporin-2 content and intracellular location: a link between the extracellular matrix and water reabsorption.
Cano-Peñalver JL; Griera M; Serrano I; Rodríguez-Puyol D; Dedhar S; de Frutos S; Rodríguez-Puyol M
FASEB J; 2014 Aug; 28(8):3645-59. PubMed ID: 24784577
[TBL] [Abstract][Full Text] [Related]
9. Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).
Armstrong SP; Seeber RM; Ayoub MA; Feldman BJ; Pfleger KD
PLoS One; 2013; 8(6):e65885. PubMed ID: 23762448
[TBL] [Abstract][Full Text] [Related]
10. Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene.
Yun J; Schöneberg T; Liu J; Schulz A; Ecelbarger CA; Promeneur D; Nielsen S; Sheng H; Grinberg A; Deng C; Wess J
J Clin Invest; 2000 Dec; 106(11):1361-71. PubMed ID: 11104789
[TBL] [Abstract][Full Text] [Related]
11. Mouse model of inducible nephrogenic diabetes insipidus produced by floxed aquaporin-2 gene deletion.
Yang B; Zhao D; Qian L; Verkman AS
Am J Physiol Renal Physiol; 2006 Aug; 291(2):F465-72. PubMed ID: 16434568
[TBL] [Abstract][Full Text] [Related]
12. P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus.
Zhang Y; Peti-Peterdi J; Müller CE; Carlson NG; Baqi Y; Strasburg DL; Heiney KM; Villanueva K; Kohan DE; Kishore BK
J Am Soc Nephrol; 2015 Dec; 26(12):2978-87. PubMed ID: 25855780
[TBL] [Abstract][Full Text] [Related]
13. Genetic deletion of the nuclear factor of activated T cells 5 in collecting duct principal cells causes nephrogenic diabetes insipidus.
Petrillo F; Chernyakov D; Esteva-Font C; Poulsen SB; Edemir B; Fenton RA
FASEB J; 2022 Nov; 36(11):e22583. PubMed ID: 36197017
[TBL] [Abstract][Full Text] [Related]
14. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
15. A mini-review of pharmacological strategies used to ameliorate polyuria associated with X-linked nephrogenic diabetes insipidus.
Mortensen LA; Bistrup C; Jensen BL; Hinrichs GR
Am J Physiol Renal Physiol; 2020 Nov; 319(5):F746-F753. PubMed ID: 32924547
[TBL] [Abstract][Full Text] [Related]
16. Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus.
Boone M; Kortenoeven M; Robben JH; Deen PM
Nephrol Dial Transplant; 2010 Jan; 25(1):48-54. PubMed ID: 19666909
[TBL] [Abstract][Full Text] [Related]
17. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo.
Sangkuhl K; Schulz A; Römpler H; Yun J; Wess J; Schöneberg T
Hum Mol Genet; 2004 May; 13(9):893-903. PubMed ID: 14998935
[TBL] [Abstract][Full Text] [Related]
18. Physiological insights into novel therapies for nephrogenic diabetes insipidus.
Sands JM; Klein JD
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1149-F1152. PubMed ID: 27534996
[TBL] [Abstract][Full Text] [Related]
19. [Nephrogenic syndrome of inappropriate antidiuresis].
Nawal B; Izzedine H; Haddiya I; Bentata Y
Pan Afr Med J; 2019; 32():210. PubMed ID: 31312322
[TBL] [Abstract][Full Text] [Related]
20. Site-1 protease-derived soluble (pro)renin receptor targets vasopressin receptor 2 to enhance urine concentrating capability.
Wang F; Xu C; Luo R; Peng K; Ramkumar N; Xie S; Lu X; Zhao L; Zuo CJ; Kohan DE; Yang T
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
